JP-2026071342-A5 -

Dates

Publication Date

20260511

Application Date

20260205

Description

The results are shown in Figure 1. After administration of omalizumab, the recovery time to the initial free IgE concentration was approximately 21 days; after administration of AB1904Am10, the recovery time to the initial free IgE concentration was approximately 28 days; and after administration of AB1904Am15, the recovery time to the initial free IgE concentration was approximately 42–56 days. This application provides the following: 1. An antigen-binding protein containing an antibody light chain variable region (VL), wherein the VL contains amino acid mutations at one or more positions selected from the group consisting of E55 and V104, compared to the amino acid sequence shown in SEQ ID NO: 22. 2. The antigen-binding protein described in 1 above, wherein VL contains an amino acid mutation at one or more positions selected from the group consisting of D30b, V29, D30, Y30a, and G30c. 3. The antigen-binding protein described in any of 1 or 2 above, wherein VL contains amino acid mutations at the following positions: D30b, E55, and V104. 4. VL is, (1) D30b, E55, V104, V29, D30, and Y30a; (2) D30b, E55, V104, D30, Y30a and G30c; (3) D30b, E55, V104 and Y30a; (4) D30b, E55, V104, Y30a and G30c; (5) D30b, E55, V104, D30, Y30a and G30c; and (6) D30b, E55, V104, D30 and Y30a An antigen-binding protein according to any one of the above 1 to 3, comprising an amino acid mutation at a position selected from any group consisting of the above. 5. An antigen-binding protein as described in any of items 1 to 4 above, wherein the amino acid mutation at position E55 includes E55Q. 6. An antigen-binding protein as described in any of items 1 to 5 above, wherein the amino acid mutation at position V104 includes V104L. 7. An antigen-binding protein according to any of items 2 to 6 above, wherein the amino acid mutation at position D30b includes D30bE. 8. An antigen-binding protein according to any of items 2 to 7 above, wherein the amino acid mutation at position V29 includes V29L. 9. An antigen-binding protein according to any one of items 2 to 8 above, wherein the amino acid mutation at position Y30a is selected from the group consisting of Y30A, Y30aS, and Y30aD. 10. An antigen-binding protein according to any one of items 2 to 9 above, wherein the amino acid mutation at position D30 is selected from the group consisting of D30Y, D30A, D30E, D30F, D30G, and D30N. 11. An antigen-binding protein according to any of items 2 to 10 above, wherein the amino acid mutation at position G30c is selected from the group consisting of G30cA, G30cY, and G30cW. 12. An antigen-binding protein as described in any of items 2 to 11 above, wherein VL contains amino acid mutations from the following groups: D30bE, E55Q, and V104L. 13. An antigen-binding protein according to any one of 1 to 12 above, wherein VL contains the amino acid sequence shown in Sequence ID No. 57. 14. An antigen-binding protein according to any one of items 1 to 13 above, wherein VL contains one of the amino acid sequences shown in SEQ ID NOs. 23 to 34. 15. An antigen-binding protein according to any one of items 1 to 14 above, comprising an antibody heavy chain variable region (VH), wherein the VH contains amino acid mutations at one or more positions selected from the group consisting of I37, A49, S50, and D54, compared to the amino acid sequence shown in SEQ ID NO: 50. 16. The antigen-binding protein described in 15 above, wherein VH contains an amino acid mutation at one or more positions selected from the group consisting of N60, P61, I67, T30, S31, S96, and H97. 17. An antigen-binding protein according to any of items 15-16 above, wherein VH contains amino acid mutations at the following positions: N60, P61, I67, I37, A49, S50, and D54. 18. VH is, (1) N60, P61, I67, I37, A49, S50, D54, S96 and H97; (2) N60, P61, I67, I37, A49, S50, D54 and T30; (3) N60, P61, I67, I37, A49, S50, D54 and S96; (4) N60, P61, I67, I37, A49, S50, D54 and S31; and (5) N60, P61, I67, I37, A49, S50, D54 and H97 An antigen-binding protein according to any one of the above 15 to 17, comprising an amino acid mutation at a position selected from any group consisting of the above. 19. An antigen-binding protein as described in any of items 15-18 above, wherein the amino acid mutation at position I37 includes I37V. 20. An antigen-binding protein as described in any of items 15 to 19 above, wherein the amino acid mutation at position A49 includes A49S. 21. An antigen-binding protein according to any of items 15 to 20 above, wherein the amino acid mutation at position S50 includes S50V. 22. An antigen-binding protein as described in any of items 15 to 21 above, wherein the amino acid mutation at position D54 includes D54A. 23. An antigen-binding protein according to any of items 16 to 22 above, wherein the amino acid mutation at position N60 includes N60A. 24. An antigen-binding protein as described in any of items 16 to 23 above, wherein the amino acid mutation at position P61 includes P61D. 25